Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

AYTU


Top 10 Correlated ETFs

AYTU


Top 10 Correlated Stocks

AYTU


In the News

10:08 30 Sep 2022 AYTU

Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript

Start Time: 16:30 January 1, 0000 5:12 PM ET Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2022 Earnings Conference Call September 27, 2022, 16:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Mark Oki - CFO Robert Blum - Lytham Partners Conference Call Participants Vernon Bernardino - H.C. Wainwright Sumant Kulkarni - Canaccord Operator Good afternoon everyone and welcome to Aytu BioPharma's Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.

08:00 30 Sep 2022 AYTU

Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022

ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal year ended June 30, 2022, after the market close on Tuesday, September 27, 2022. The Company has scheduled a conference call that same day, Tuesday, September 27, 2022, at 4:30 pm ET, to review the results.

08:00 30 Sep 2022 AYTU

Aytu BioPharma to Participate in September 2022 Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.

09:11 30 Sep 2022 AYTU

Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:54 30 Sep 2022 AYTU

Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?

Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

01:03 30 Sep 2022 AYTU

Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status

The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.

09:31 30 Sep 2022 AYTU

Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript

Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript

08:05 30 Sep 2022 AYTU

Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021

ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the first quarter fiscal 2022 and provide an overview of its business and growth strategy.

04:47 30 Sep 2022 AYTU

Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aytu BioPharma Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

04:49 30 Sep 2022 AYTU

ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are a stockholder of Aytu BioPharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at:  http://www.rowleylawpllc.com/investigation/aytu /.

Financial details

Company Rating
Neutral
Market Cap
11.72M
Income
-111.47M
Revenue
92.7M
Book val./share
2.06
Cash/share
0.93
Dividend
-
Dividend %
-
Employees
175
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
-0.03
Forward P/E
-0
PEG
-0.01
P/S
0.03
P/B
0.07
P/C
0.2
P/FCF
-0.11
Quick Ratio
0.64
Current Ratio
0.93
Debt / Equity
0.27
LT Debt / Equity
0.27
-
-
EPS (TTM)
-4.13
EPS next Y
-206.98
EPS next Q
-0.67
EPS this Y
16%
EPS next Y
4911.5%
EPS next 5Y
4911.5%
EPS last 5Y
-79.52%
Revenue last 5Y
82.73%
Revenue Q/Q
4.64%
EPS Q/Q
306.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
12.19%
Inst Trans
-8.94%
ROA
-80%
ROE
-136%
ROC
-1.52%
Gross Margin
54%
Oper. Margin
-115%
Profit Margin
-114%
Payout
-
Shs Outstand
62.43M
Shs Float
35.32M
-
-
-
-
Target Price
11
52W Range
0.18-3.29
52W High
-
52W Low
-
RSI
21
Rel Volume
0.03
Avg Volume
1.28M
Volume
39K
Perf Week
-8.28%
Perf Month
-34.32%
Perf Quarter
-81.61%
Perf Half Y
-83.43%
-
-
-
-
Beta
-0.273671
-
-
Volatility
0%, 0.03%
Prev Close
-0.27%
Price
0.1839
Change
-3.21%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-06-30

Metric History 2017-06-302018-06-302019-06-302020-06-30 2021-06-30
Revenue per share
1.38K54.999.396.113.92
Net income per share
-9.66K-153.06-34.81-3.01-3.48
Operating cash flow per share
-5.94K-239.49-17.75-6.28-1.55
Free cash flow per share
-5.98K-240.61-17.82-6.28-1.55
Cash per share
344.35105.3614.1710.642.96
Book value per share
1.72K201.699.0921.028.21
Tangible book value per share
-3.14K30.93-15.394-0.82
Share holders equity per share
1.72K201.699.0921.028.21
Interest debt per share
1.09K11.2600.561.69
Market cap
5.5M3.73M12.47M61.91M66.48M
Enterprise value
4.7M-3.29M1.43M16.35M45.18M
P/E ratio
-0.24-0.37-0.46-4.55-1.14
Price to sales ratio
1.711.021.72.241.01
POCF ratio
-0.4-0.23-0.9-2.18-2.56
PFCF ratio
-0.39-0.23-0.9-2.18-2.56
P/B Ratio
1.370.281.760.650.48
PTB ratio
1.370.281.760.650.48
EV to sales
1.46-0.90.190.590.69
Enterprise value over EBITDA
-0.30.48-0.06-2.22-0.93
EV to operating cash flow
-0.340.21-0.1-0.58-1.74
EV to free cash flow
-0.340.21-0.1-0.58-1.74
Earnings yield
-4.09-2.73-2.18-0.22-0.88
Free cash flow yield
-2.54-4.3-1.11-0.46-0.39
Debt to equity
0000.010.02
Debt to assets
0.730.360.80.380.48
Net debt to EBITDA
0.051.020.456.180.44
Current ratio
0.842.792.872.650.96
Interest coverage
-7.94-26.29000
Income quality
0.611.560.512.080.45
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.464.842.6300.39
Research and developement to revenue
0.420.050.080.060.09
Intangibles to total assets
0.750.540.550.50.57
Capex to operating cash flow
0.010000
Capex to revenue
-0.03-0.02-0.0100
Capex to depreciation
-0.03-0.03-0.0200
Stock based compensation to revenue
0.780.10.140.040.05
Graham number
19.32K833.4384.3937.7625.36
ROIC
-1.77-1.12-0.57-0.17-0.38
Return on tangible assets
-6.12-1.05-1.73-0.18-0.51
Graham Net
-3.92K7.22-18.68-0.19-2.93
Working capital
-581.91K6.08M10.06M46.66M-4.2M
Tangible asset value
-7.32M2.06M-12M18.07M-13.7M
Net current asset value
-7.97M1.83M-12.2M17.14M-22.87M
Invested capital
0000.030.21
Average receivables
2.85M2.88M3.46M5.18M16.68M
Average payables
7.02M6.97M7.06M11.82M15.54M
Average inventory
5.66M5.67M5.72M10M13.17M
Days sales outstanding
59.8257.7286.868.37156.7
Days payables outstanding
571.8377.3380.78571.42192.91
Days of inventory on hand
337.93238.34238.7483.22163.69
Receivables turnover
6.16.324.215.342.33
Payables turnover
0.640.970.960.641.89
Inventory turnover
1.081.531.530.762.23
ROE
-5.63-0.76-3.83-0.14-0.42
Capex per share
-47.9-1.12-0.0800

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q3

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.7510.860.880.82
Net income per share
-1.41-0.81-1.09-0.44-1.79
Operating cash flow per share
-0.49-0.27-0.15-0.33-0.31
Free cash flow per share
-0.49-0.27-0.15-0.33-0.31
Cash per share
2.572.111.571.340.93
Book value per share
7.915.854.3642.06
Tangible book value per share
-1.04-0.58-4.19-0.84-0.74
Share holders equity per share
7.915.854.3642.06
Interest debt per share
1.481.210.420.470.72
Market cap
137.5M117.83M73.72M35.66M32.07M
Enterprise value
117.8M96.53M44.1M12.78M25.71M
P/E ratio
-1.35-1.55-0.66-0.77-0.15
Price to sales ratio
10.25.023.371.541.33
POCF ratio
-15.67-18.75-19.45-4.04-3.52
PFCF ratio
-15.67-18.75-19.45-4.04-3.52
P/B Ratio
0.960.860.660.340.52
PTB ratio
0.960.860.660.340.52
EV to sales
8.744.112.010.551.06
Enterprise value over EBITDA
-6.14-4.87-1.74-1.44-0.51
EV to operating cash flow
-13.42-15.36-11.63-1.45-2.82
EV to free cash flow
-13.42-15.36-11.63-1.45-2.82
Earnings yield
-0.19-0.16-0.38-0.32-1.66
Free cash flow yield
-0.06-0.05-0.05-0.25-0.28
Debt to equity
0.140.020.070.080.27
Debt to assets
0.470.480.840.530.64
Net debt to EBITDA
1.031.071.172.580.13
Current ratio
1.20.960.910.870.97
Interest coverage
00000
Income quality
0.340.330.140.760.17
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.360.380.340.31
Research and developement to revenue
0.030.20.10.210.15
Intangibles to total assets
0.60.570.940.570.49
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0.110.050.070.050.05
Graham number
15.8310.3110.336.279.1
ROIC
-0.14-0.15-0.68-0.09-0.62
Return on tangible assets
-0.23-0.17-3.11-0.12-0.62
Graham Net
-2.9-2.09-2.01-2.18-1.77
Working capital
16.33M-4.2M-8.96M-13.03M-2.41M
Tangible asset value
-18.89M-13.7M-107.27M-22.15M-21.92M
Net current asset value
-28.39M-22.87M-27.19M-30.75M-29.74M
Invested capital
0.190.210.10.120.35
Average receivables
25.61M25.58M22.31M22.99M25.3M
Average payables
00000
Average inventory
16.57M16.45M16.44M16.56M15.22M
Days sales outstanding
188.44107.9988.8989.47102.7
Days payables outstanding
108.721340087.01
Days of inventory on hand
109.03113.71155.52137.65108.59
Receivables turnover
0.480.831.011.010.88
Payables turnover
0.830.67001.03
Inventory turnover
0.830.790.580.650.83
ROE
-0.18-0.14-0.25-0.11-0.87
Capex per share
00000

Frequently Asked Questions

What is Aytu BioPharma, Inc. stock symbol ?

Aytu BioPharma, Inc. is a US stock , located in Englewood of Colorado and trading under the symbol AYTU

Is Aytu BioPharma, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $11. The lowest prediction is $11 and the highest is $11

What is AYTU stock prediction ?